| 2022-02-11 | ALTSHULER DAVID | EVP, Global Research and CSO | Sell | 2,297 | $235.02 | $539,836.69 | -0.9% | → |
| 2022-02-11 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Sell | 248 | $234.79 | $58,227.44 | -0.1% | → |
| 2022-02-02 | Sanna Bastiano | EVP, Cell & Genetic Therapies | Sell | 1,040 | $250.98 | $261,016.94 | -0.4% | → |
| 2022-02-02 | ALTSHULER DAVID | EVP, Global Research and CSO | Sale+OE | 4,660 | $251.47 | $1,171,842.12 | -1.0% | → |
| 2022-02-02 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | Sell | 2,944 | $250.07 | $736,206.08 | -4.9% | → |
| 2022-01-28 | MCGLYNN MARGARET G | Director | Sale+OE | 5,000 | $241.79 | $1,208,960.27 | -33.3% | → |
| 2021-11-15 | Sachdev Amit | EVP, Chief Patient Officer | Sell | 51 | $187.19 | $9,546.78 | - | → |
| 2021-11-15 | Arbuckle Stuart A | EVP, COO | Sell | 3 | $187.26 | $561.78 | - | → |
| 2021-11-15 | ALTSHULER DAVID | EVP, Global Research and CSO | Sell | 34 | $187.22 | $6,365.40 | - | → |
| 2021-08-19 | Kewalramani Reshma | CEO & President | Buy | 10,000 | $195.65 | $1,956,491.60 | +7.5% | → |
| 2021-08-02 | SACHS BRUCE I | Director | Buy | 15,000 | $197.91 | $2,968,650.00 | +57.2% | → |
| 2021-06-02 | Bhatia Sangeeta N. | Director | Sell | 559 | $209.69 | $117,216.13 | -3.4% | → |
| 2021-05-17 | Arbuckle Stuart A | EVP, Chief Comm & Ops Officer | Sell | 109 | $216.41 | $23,588.67 | - | → |
| 2021-05-17 | ALTSHULER DAVID | EVP, Global Research and CSO | Sell | 79 | $216.36 | $17,092.79 | - | → |
| 2021-05-17 | Liu Joy | SVP, General Counsel | Sell | 112 | $216.34 | $24,230.11 | -0.7% | → |
| 2021-05-17 | Sachdev Amit | EVP, Chief Patient Officer | Sell | 45 | $216.35 | $9,735.87 | - | → |
| 2021-05-17 | Sanna Bastiano | EVP, Cell & Genetic Therapies | Sell | 112 | $216.34 | $24,230.11 | -0.2% | → |
| 2021-05-03 | Sanna Bastiano | EVP, Cell & Genetic Therapies | Sell | 459 | $218.83 | $100,442.97 | -1.3% | → |